HomeBenefit ▶ Tenth Annual ATS Foundation Research Program Benefit
Tenth Annual ATS Foundation Research Program Benefit

James Donohue and Dean Schraufnagel

James F. Donohue, MD (Left), receiving the
2018 Breathing for Life Award from
Dean Schraufnagel, MD, ATS Foundation Chair

With an assortment of hors d’oeuvres, music, and dancing the ATS Foundation kicked off its Tenth Annual Research Program Benefit on Saturday, May 19, 2018. More than 700 attendees gathered at the Manchester Grand Hyatt San Diego to recognize James Donohue, MD, as the recipient of the 2018 Breathing for Life Award, as well as honor grant awardees, celebrate the ATS Foundation Research Program’s successes, and socialize with friends.

The Breathing for Life Award is given by the ATS Foundation to recognize philanthropy and scientific accomplishments. Dr. Donohue chaired the ATS Foundation from 2010 to 2016. During that time, annual contributions to the Research Program nearly tripled to $1 million, and the number of research grants awarded doubled. Dr. Donohue, who is division director emeritus of pulmonary diseases and critical care medicine at the University of North Carolina, Chapel Hill, is known as a master clinician and clinical scientist who led trials of the most commonly used inhaled therapies for COPD and asthma.

The gala raised more than $472,000 from corporate, medical institution, and individual supporters with proceeds supporting research grants for young investigators.

In 2018, the ATS Foundation will fund more than 30 awards, including unrestricted research awards in pulmonary, critical care, and sleep medicine; research partner awards; and awards for outstanding alumni from the Methods in Epidemiologic, Clinical, and Operations Research (MECOR) program. Since 2004, the ATS Foundation Research Program has provided $17.6 million in grants to more than 235 investigators, who have gone on to secure $268 million in federal funding.

VIDEO: Dr. James Donohue, MD, 2018 Breathing for Life Awardee

VIEW: Photo gallery

The ATS Foundation thanks Genentech for support at the Sapphire Level for the Tenth Annual ATS Foundation Research Program Benefit; AstraZeneca LP and Boehringer Ingelheim Pharmaceuticals, Inc. at the Gold Level; Freeman, Gilead Sciences, Inc., Insmed Incorporated, Mallinckrodt Pharmaceuticals, Sunovion Pharmaceuticals, Inc., and Theravance at the Silver Level; Ascend Integrated Media, Circassia Pharmaceuticals, Grifols, GlaxoSmithKline, NBRC, Novartis, and Vertex Pharmaceuticals, Inc. at the Bronze Level.

The ATS Foundation also thanks the many individuals and medical institutions that have stepped forward to support the Research Program and young investigators in pulmonary, critical care, and sleep medicine.

The ATS supports the ATS Foundation’s administrative expenses, assuring that every dollar contributed goes directly to support programs.